Autor: Firma Allero Therapeutics B.V

Allero Therapeutics‘ Immunotherapy Approach in Food-Induced Immune Disorders Validated by Two Peer-Reviewed Publications

16. März 20217. Mai 2021 Firma Allero Therapeutics B.VForschung und Entwicklungallergy, allero, alleros, cells, clinical, immunotherapy, intake, mrna, onset, oromucosal, patients, privilege, tbp, treatment, with

Allero Therapeutics BV, a Dutch oromucosal immunotherapy company, today announced the publication of two studies further detailing and validating its approach to combat food-induced immune disorders with its SOMIT (Specific OroMucosal ImmunoTherapy) platform technology. The first study, published with collaborators Mehr

Allero Therapeutics and Abbreos join forces to clinically develop COVID-19 program

24. November 20207. Mai 2021 Firma Allero Therapeutics B.VForschung und Entwicklungcic, clinical, covid, financial, immunoglobulin, ivig, lethal, market, medical, new, patients, syndrome, treatment, wave, with

Allero Therapeutics BV, a Belgian-Dutch oromucosal immunotherapy company, and Abbreos Inc., a US- based IND-stage company focused on developing treatments that dampen hyperactive immune responses, today announced a clinical development agreement to treat medical conditions associated with potentially lethal amounts Mehr